Preprint reports an uncharacterized impurity in compounded tirzepatide plus B12 products

A preprint posted March 9, 2026, reports that researchers found a previously uncharacterized impurity in ten compounded tirzepatide products that also contained vitamin B12 ^[1]. The samples were obtained from multiple compounding pharmacies, medical spas, and telehealth networks ^[1]. According to the paper, the impurity formed through a chemical interaction between tirzepatide and B12, and in some samples it made up as much as 10% of the total protein content ^[1].

The authors say there are currently no data on whether this impurity affects the safety or effectiveness of the drug ^[1]. The paper has not been peer reviewed, meaning outside scientists have not yet checked the methods or conclusions ^[1]. Preprints are often used to share early findings quickly, but they can change, be corrected, or be withdrawn during the review process.

Tirzepatide is the active ingredient in the FDA-approved drugs Mounjaro and Zepbound. Compounded versions, including those combined with B12, are not FDA-approved and are typically made by compounding pharmacies rather than the drug's original manufacturer. The preprint does not name the specific pharmacies, spas, or telehealth companies whose products were tested, and it is not yet known how common this impurity is across the broader compounded tirzepatide-B12 market ^[1].

Why it matters for patients

Many people using compounded tirzepatide products, sometimes sold with added B12, do so through telehealth services or med spas rather than through prescriptions for the brand-name drugs. This preprint raises a question about what else may be present in those products beyond the labeled ingredients, but it does not answer whether the impurity found causes harm, changes how well the drug works, or has no effect at all ^[1].

Because the interaction described happens between tirzepatide and B12 specifically, the finding may be most relevant to combination products rather than compounded tirzepatide alone, though the sources do not address that distinction directly. The study also does not say whether the impurity level varies by how a product is stored, mixed, or how long it has been on the shelf.

Patients who use compounded GLP-1 products with B12 may want to know that this is an early, unreviewed finding, not a confirmed safety problem. At the same time, the presence of an unidentified compound at levels as high as 10% of protein content in some tested samples is something regulators, compounders, and independent labs may look at more closely as the science develops ^[1].

What happens next

The preprint has not yet gone through peer review, so its findings could be revised, expanded, or challenged by other scientists ^[1]. It is not yet known whether the FDA, state pharmacy boards, or the compounding pharmacies named indirectly in the study will respond, test additional samples, or issue guidance. It is also not known whether follow-up studies will identify what the impurity actually is or test its biological effects in animals or humans. Readers should expect that any regulatory or manufacturer response, if it comes, would likely reference this preprint by its posting date of March 9, 2026 ^[1].